GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ZimVie Inc (NAS:ZIMV) » Definitions » ROE %
中文

ZimVie (ZimVie) ROE % : -239.25% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

ZimVie Definition

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. ZimVie's annualized net income for the quarter that ended in Dec. 2023 was $-1,339.4 Mil. ZimVie's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $559.8 Mil. Therefore, ZimVie's annualized ROE % for the quarter that ended in Dec. 2023 was -239.25%.

The historical rank and industry rank for ZimVie's ROE % or its related term are showing as below:

ZIMV' s ROE % Range Over the Past 10 Years
Min: -67.34   Med: -6.48   Max: -1.68
Current: -58.7

During the past 6 years, ZimVie's highest ROE % was -1.68%. The lowest was -67.34%. And the median was -6.48%.

ZIMV's ROE % is ranked worse than
79.53% of 811 companies
in the Medical Devices & Instruments industry
Industry Median: 0.29 vs ZIMV: -58.70

ZimVie ROE % Historical Data

The historical data trend for ZimVie's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZimVie Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -1.68 -11.34 -6.48 -5.78 -67.34

ZimVie Quarterly Data
Dec18 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.27 -15.96 -12.71 -2.83 -239.25

Competitive Comparison

For the Medical Devices subindustry, ZimVie's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZimVie ROE % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, ZimVie's ROE % distribution charts can be found below:

* The bar in red indicates where ZimVie's ROE % falls into.



ZimVie ROE % Calculation

ZimVie's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-393.282/( (758.604+409.493)/ 2 )
=-393.282/584.0485
=-67.34 %

ZimVie's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-1339.408/( (710.199+409.493)/ 2 )
=-1339.408/559.846
=-239.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


ZimVie  (NAS:ZIMV) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-1339.408/559.846
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1339.408 / -783.048)*(-783.048 / 1356.633)*(1356.633 / 559.846)
=Net Margin %*Asset Turnover*Equity Multiplier
=171.05 %*-0.5772*2.4232
=ROA %*Equity Multiplier
=-98.73 %*2.4232
=-239.25 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-1339.408/559.846
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-1339.408 / 123.316) * (123.316 / 87.976) * (87.976 / -783.048) * (-783.048 / 1356.633) * (1356.633 / 559.846)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= -10.8616 * 1.4017 * -11.24 % * -0.5772 * 2.4232
=-239.25 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


ZimVie ROE % Related Terms

Thank you for viewing the detailed overview of ZimVie's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


ZimVie (ZimVie) Business Description

Traded in Other Exchanges
Address
10225 Westmoor Drive, Westminster, CO, USA, 80021
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
Executives
Camber Capital Management Lp 10 percent owner 101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
Sally Crawford director C/O HOLOGIC, INC., BEDFORD MA 01730
Vafa Jamali director, officer: See Remarks C/O ZIMVIE INC., 10225 WESTMOOR DRIVE, WESTMINSTER CO 80021
Richard Heppenstall officer: See Remarks C/O ZIMVIE INC., 10225 WESTMOOR DRIVE, WESTMINSTER CO 80021
Zimmer Biomet Holdings, Inc. 10 percent owner 345 EAST MAIN STREET, WARSAW IN 46580
Richard Kuntz director MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Vinit K Asar director 10910 DOMAIN DRIVE, SUITE 300, AUSTIN TX 78758
Karen Matusinec director C/O ZIMVIE INC., 10225 WESTMOOR DRIVE, WESTMINSTER CO 80021
David P King director PRIVIA HEALTH GROUP, INC., 950 N. GLEBE RD., SUITE 700, ARLINGTON VA 22203
Rebecca Ann Whitney officer: See Remarks 10225 WESTMOOR DRIVE, WESTMINSTER CO 80021
David John Harmon officer: See Remarks 10225 WESTMOOR DRIVE, WESTMINSTER CO 80021
Indraneel Kanaglekar officer: See Remarks C/O ZIMVIE INC., 10225 WESTMOOR DRIVE, WESTMINSTER CO 80021
Heather Kidwell officer: See Remarks C/O ZIMVIE INC., 10225 WESTMOOR DRIVE, WESTMINSTER CO 80021
Sandra Schneider officer: Chief Accounting Officer C/O ZIMVIE INC., 10225 WESTMOOR DRIVE, WESTMINSTER CO 80021